STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) — Springworks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Dr. Martin MacKay to the company’s Board of Directors. Dr. MacKay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotechnology research and development experience, including leadership roles at Pfizer, AstraZeneca and Alexion.
“Martin is a proven industry leader with extraordinary experience in developing new therapies and delivering them to patients who need them,” said Saqib Islam, Springworks’ chief executive officer. “His expertise in rare diseases and unique perspective leading multiple research and development organizations around the world will be invaluable to Springworks as we advance and expand our pipeline and fulfill our mission to make a meaningful difference in patients’ lives. We are pleased to welcome Martin to the Springworks team.”
“I am excited to join the SpringWorks board and work with a group of talented and visionary leaders who are driven by a shared mission to develop and deliver innovative therapies to patients with serious illnesses,” said Dr. MacKay. “I believe SpringWorks is uniquely positioned to make a significant impact on a therapeutic area with great potential, and I am honored to contribute my experience and knowledge to the important work SpringWorks is doing.”
Dr. MacKay is co-founder and Chairman of the Board of Rallybio, a privately held, clinical-stage biotechnology company focused on severe rare diseases, founded in January 2018. Dr. MacKay previously served as Head of Research and Development and Executive Vice President at Alexion from 2013 to 2017. Prior to joining Alexion, he served as President of Research and Development at AstraZeneca from 2010 to 2013, where he led the company’s worldwide research and development functions, including discovery research, clinical development, regulatory affairs and key related research and development functions. From 1995 to 2009, Dr. MacKay held various positions at Pfizer, including serving as part of the executive leadership team as Senior Vice President, Worldwide Development, where he led a global organization driving a portfolio of investigational medicines across multiple disease areas, and as President and Head of Pfizer Pharma Therapeutics Research and Development, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. From 1986 to 1995, Dr. Mackay worked for Ciba-Geigy (now Novartis) in the UK and Switzerland and prior to that held various positions in academic research. Dr. Mackay currently serves on the board of directors of Charles River Laboratories and Novo Nordisk. He holds an honours degree in Microbiology from Heriot-Watt University and a PhD in Molecular Genetics from the University of Edinburgh.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to the development and delivery of life-changing medicines for people living with serious rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with advanced desmoid tumors requiring systemic therapy, is the company’s first FDA-approved treatment. SpringWorks also has a diverse pipeline of targeted therapies spanning solid tumors and hematological cancers, with programs in preclinical development through advanced clinical trials. In addition to its own owned programs, SpringWorks is engaged in multiple collaborations with innovators in industry and academia to maximize the potential of its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
contact address:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director of Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com
